Patient-reported outcome Research (Qol, fatigue, sleep, cognition, anxiety, depression)

Register studies

• SarcBOP “A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Soft-tissue and Bone Sarcoma”
  A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Soft-tissue and Bone Sarcoma.
  In cooporation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
  
  
• MyBOP „A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Myeloid Neoplasms“
  The Myeloid Neoplasms Biology and Outcome Project
  In cooporation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg

Clinical studies

• COGNITION-GUIDE
  Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse.
  In cooportaion with Prof. A. Schneeweiss and Prof. R. Schlenk, National Center for Tumor Diseases (NCT), Heidelberg
  
  
• CRAFT: NCT-PMO-1602, Metastatic or locally advanced malignancies, NCT04551521
  
  
• NCT-PMO-1603/TOP-ART, Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies, NCT03127215
  
  
• NCT/DKTK-PMO-1604, Metastatic and Locally Advanced NRG1-rearranged Malignancies, NCT04410653
  
  
• CH.P.12C. (Chordoma), NCT01182779

• IntenSify
  An open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the cytostatics Gemcitabine and nab-Paclitaxel in Patients with Advanced Stage or metastatic Pancreatic Ductal Adenocarcinoma to evaluate the combination's Pharmacokinetics, Safety and Efficacy.
  In cooportaion with PD Dr. N. Hohmann, National Center for Tumor Diseases (NCT), Heidelberg
  
  
• Q-HAM “Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD”
  Phase II clinical trial.
  In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg
  
  
• GnG "Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in older patients with newly diagnosed AML"
  The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively.
  In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg

TROPHIT1
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients.
In cooperation with PD Dr. med. Bruno Christian Köhler, Medical University of Heidelberg